<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105066</url>
  </required_header>
  <id_info>
    <org_study_id>AG0017</org_study_id>
    <nct_id>NCT00105066</nct_id>
  </id_info>
  <brief_title>The Effects of Metformin on Blood Vessel Structure and Function</brief_title>
  <official_title>The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on
      the blood vessels of individuals with the Metabolic Syndrome (MeS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with the Metabolic Syndrome (MeS) are at increased risk for developing
      cardiovascular diseases. This increased risk may, in part, be related to abnormalities in the
      blood vessels. MeS is defined as having 3 or more of the following 5 criteria:

        -  Abdominal obesity (waist measurement &gt;39.8 inches in men, &gt;34.4 inches in women)

        -  Elevated triglycerides (&gt;150 mg/dl)

        -  Low HDL or &quot;good&quot; cholesterol (&lt;40 mg/dl in men or &lt;50 mg/dl in women)

        -  Elevated blood pressure (&gt;130/85) or treatment for high blood pressure

        -  Elevated fasting blood sugar (&gt;100 mg/dl)

      Metformin is a medication that is approved by the Food and Drug Administration (FDA) for the
      treatment of diabetes; however, it can also be safely administered to non-diabetic subjects.
      We are evaluating whether Metformin reduces the stiffness of blood vessels and improves
      endothelial function.

      This study requires 4 visits to the NIA Clinical Research Center (located on the premises of
      Harbor Hospital) over a 5-month period. At the initial visit, patients will be given a
      physical examination with blood and urine tests, and an EKG. They will be randomized into one
      of two groups; one group will receive Metformin (1700 mg per day), while the other group will
      receive a placebo. Participants will take the medication for 4 months. Subsequent visits will
      include additional blood tests, ultrasound and echo exams.

      Taking part in this study is entirely voluntary. All testing and medications will be provided
      at no cost to the participant or their family.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Arterial Stiffness Compared to Baseline</measure>
    <time_frame>Baseline and 4.5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Flow Mediated Dilation (FMD)</measure>
    <time_frame>Baseline and 4.5 months</time_frame>
    <description>to evaluate improvement in endothelial function</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850mg tablet once a day for one month, then twice a day for 3 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Fortamet®; Glucophage®; Glumetza™; Riomet™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet once a day for one month, then twice a day for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants with the Metabolic Syndrome, which is defined as having 3 or more of the
        following 5 alterations:

          -  Abdominal obesity (waist measurement &gt;39.8 inches in men, &gt;34.4 inches in women)

          -  Elevated triglycerides (&gt;150 mg/dl)

          -  Low HDL or &quot;good&quot; cholesterol (&lt;40 mg/dl in men or &lt;50 mg/dl in women)

          -  Elevated blood pressure (&gt;130/85) or treatment for high blood pressure

          -  Elevated fasting blood sugar (&gt;100 mg/dl)

        Exclusion Criteria:

          -  Diabetes treated with medication

          -  Blood pressure &gt;160/100 mmHg

          -  Clinical Congestive Heart Failure

          -  Anemia with hematocrit &lt;32%

          -  Asthma or Chronic Obstructive Pulmonary Disease (COPD) requiring daily medication or
             use of home oxygen therapy

          -  Major surgery planned within the next six months

          -  A recent, unexplained weight loss of &gt;10% of body weight in the past 6 months

          -  A known allergy or hypersensitivity to Metformin

          -  History of hepatitis or cirrhosis

          -  History of kidney disease (defined as serum creatinine &gt;1.4 mg/dL in men, &gt;1.3 mg/dL
             in women)

          -  Pregnancy or the absence of an effective method of contraception

          -  Illicit drug or alcohol abuse

          -  Cancer requiring treatment currently or recently completed treatment in the last 2
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Ferrucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Strait, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Aging (NIA), Harbor Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <reference>
    <citation>Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999 Jan;48(1):198-202.</citation>
    <PMID>9892243</PMID>
  </reference>
  <reference>
    <citation>Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001 Apr;37(5):1344-50.</citation>
    <PMID>11300445</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <results_first_submitted>April 25, 2013</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>triglycerides</keyword>
  <keyword>HDL</keyword>
  <keyword>LDL</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>High Cholesterol</keyword>
  <keyword>High Blood Sugar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="13.5"/>
                    <measurement group_id="B2" value="55.1" spread="11.8"/>
                    <measurement group_id="B3" value="54.4" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carotid Femoral Pulse Wave Velocity</title>
          <units>meters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="2.1"/>
                    <measurement group_id="B2" value="6.8" spread="2.1"/>
                    <measurement group_id="B3" value="6.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FMD</title>
          <description>Flow Mediated Dilation of brachial artery (percent change in blood flow after hyperemia)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="4.4"/>
                    <measurement group_id="B2" value="9.3" spread="6.1"/>
                    <measurement group_id="B3" value="8.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA-S</title>
          <description>HOMA Insulin Sensitivity Index</description>
          <units>HOMA Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="26.9"/>
                    <measurement group_id="B2" value="52.3" spread="23.1"/>
                    <measurement group_id="B3" value="52.5" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Arterial Stiffness Compared to Baseline</title>
        <time_frame>Baseline and 4.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Arterial Stiffness Compared to Baseline</title>
          <units>meters / second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="2.1"/>
                    <measurement group_id="O2" value="-7.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow Mediated Dilation (FMD)</title>
        <description>to evaluate improvement in endothelial function</description>
        <time_frame>Baseline and 4.5 months</time_frame>
        <population>Participants with complete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow Mediated Dilation (FMD)</title>
          <description>to evaluate improvement in endothelial function</description>
          <population>Participants with complete data.</population>
          <units>percentage change in diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="7.0"/>
                    <measurement group_id="O2" value="10.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Homa Insulin Sensitivity</title>
        <description>Homeostatic Model Assessment of insulin sensitivity</description>
        <time_frame>4.5 months</time_frame>
        <population>Participants with complete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Homa Insulin Sensitivity</title>
          <description>Homeostatic Model Assessment of insulin sensitivity</description>
          <population>Participants with complete data.</population>
          <units>HOMA Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" spread="36.3"/>
                    <measurement group_id="O2" value="64.5" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo : placebo tablet once a day for one month, then twice a day for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Metformin : 850mg tablet once a day for one month, then twice a day for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Strait</name_or_title>
      <organization>National Institute On Aging</organization>
      <phone>4105588084</phone>
      <email>straitj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

